Ovarian Cancer Clinical Trials in Buffalo, New York

5 studies are recruiting for ovarian cancer in Buffalo, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

   This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Comprehensive Cancer Center, Buffalo, New York

   Locations

   14 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06774963 on ClinicalTrials.gov

2. Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

   HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Comprehensive Care Center, Buffalo, New York

   Locations

   12 in total

   Run by

   Whitehawk Therapeutics, Inc.

   See if you can join NCT07444814 on ClinicalTrials.gov

3. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

   Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Cancer Institute, Buffalo, New York

   Locations

   18 in total

   Run by

   Incyclix Bio

   See if you can join NCT05735080 on ClinicalTrials.gov

4. A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

   The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park, Buffalo, New York

   Locations

   4 in total

   Run by

   Outpace Bio, Inc.

   See if you can join NCT07030907 on ClinicalTrials.gov

5. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Buffalo, New York

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov